```html

Cushing's Disease – A Complete Patient‑Friendly Guide

Overview

Cushing’s disease is a rare endocrine disorder caused by a tumor in the pituitary gland that produces excess adrenocorticotropic hormone (ACTH). The surge of ACTH stimulates the adrenal glands to release too much cortisol, the body’s primary “stress hormone.” Elevated cortisol affects many organ systems, leading to the characteristic physical changes and metabolic problems associated with the condition.

Although the term “Cushing’s syndrome” refers to any cause of cortisol excess, “Cushing’s disease” specifically denotes the pituitary‑origin form. It accounts for roughly 70 % of endogenous Cushing’s cases.<sup>[1]</sup>

Who is affected? The disease most commonly appears in adults between 20 and 50 years of age, with a female‑to‑male ratio of about 3:1.<sup>[2]</sup> Pediatric cases are rare (<5 % of all cases) but tend to present with more rapid growth stunting. The overall prevalence is estimated at 2–3 cases per million people per year, making it one of the least common hormonal disorders.<sup>[3]</sup>

Symptoms

Cortisol excess produces a wide spectrum of signs that may develop slowly over months or years. Not every patient experiences every symptom, and the severity varies with cortisol levels, tumor size, and individual sensitivity.

Classic physical features

• Central (abdominal) obesity: Rounded “moon‑shaped” face and a fatty “buffalo hump” between the shoulder blades.
• Skin changes: Thin, fragile skin that bruises easily, purple or pink striae (stretch marks) on the abdomen, thighs, breasts, or arms.
• Facial rounding: “Moon face” due to fat deposition on the cheeks.
• Muscle weakness: Proximal muscle atrophy leading to difficulty climbing stairs or lifting objects.
• Acne & hirsutism: Increased oil production and excess hair growth in women (often on the chin, chest, abdomen).

Metabolic and systemic symptoms

• Hyperglycemia/diabetes mellitus: Cortisol antagonizes insulin, raising blood sugar.
• Hypertension: Occurs in up to 80 % of patients.
• Weight gain: Despite appetite loss in some, many gain 10–20 kg.
• Osteoporosis & fractures: Cortisol inhibits bone formation and calcium absorption.
• Fatigue and sleep disturbances: Insomnia, early‑morning awakening.
• Neuropsychiatric changes: Mood swings, depression, anxiety, irritability, and in severe cases, psychosis.
• Immunosuppression: Frequent infections, poor wound healing.
• Menstrual irregularities & infertility: Oligomenorrhea or amenorrhea in women; decreased libido and erectile dysfunction in men.

Rare or later‑stage manifestations

• High potassium (hypokalemia) and metabolic alkalosis (especially with ectopic ACTH production).
• Gastrointestinal ulcers.
• Pituitary apoplexy – sudden hemorrhage into the tumor causing severe headache, vision loss, or altered consciousness.

Causes and Risk Factors

Cushing’s disease is caused by a benign (non‑cancerous) adenoma of the anterior pituitary gland that secretes ACTH autonomously. The excess ACTH drives the adrenal cortex to overproduce cortisol.

Main cause

• Pituitary corticotroph adenoma: Represents >70 % of endogenous Cushing’s.

Risk factors

• Sex: Women are three times more likely to develop pituitary tumors.
• Age: Peak incidence between 30–45 years.
• Family history of pituitary tumors: Rare hereditary syndromes (e.g., Multiple Endocrine Neoplasia type 1, Carney complex) increase risk.
• Radiation exposure: Prior cranial irradiation (for other cancers) has been linked to later pituitary adenomas.
• Other endocrine disorders: Pre‑existing adrenal hyperplasia or ectopic ACTH‑secreting tumors can mimic disease but are distinct etiologies.

Diagnosis

Because early symptoms overlap with common conditions (obesity, hypertension, depression), a high index of suspicion is essential. Diagnosis proceeds in two stages: confirming cortisol excess, then identifying its source.

Biochemical screening

• 24‑hour urinary free cortisol (UFC): Measures unbound cortisol excreted in urine; two elevated collections on separate days confirm excess.
• Late‑night salivary cortisol: Cortisol should be lowest at midnight; values >5 µg/dL are abnormal.
• Low‑dose dexamethasone suppression test (LDDST): 1 mg dexamethasone at 11 p.m.; cortisol >1.8 µg/dL the next morning indicates lack of suppression.

Identifying the source (ACTH‑dependent vs. independent)

• Plasma ACTH level: Detectable/elevated ACTH suggests pituitary or ectopic source; undetectable ACTH points to adrenal tumor.
• High‑dose dexamethasone suppression test (HDDST): Suppression (>50 % drop) favors pituitary disease; lack of suppression suggests ectopic ACTH.
• Pituitary MRI: First‑line imaging; microadenomas (<10 mm) are found in ~60 % of patients, macroadenomas (>10 mm) in ~30 %.
• Inferior petrosal sinus sampling (IPSS): Considered the gold standard when MRI is inconclusive; compares ACTH levels from veins draining the pituitary vs. peripheral blood.

Additional assessments

• Bone density scan (DEXA) to evaluate osteoporosis.
• Blood glucose and lipid profile for metabolic impact.
• Eye examination if a macroadenoma threatens the optic chiasm.

Treatment Options

The therapeutic goal is to normalize cortisol production while preserving pituitary function. Treatment choice depends on tumor size, invasiveness, patient age, and comorbidities.

Surgical management

• Transsphenoidal pituitary surgery: Endoscopic or microscopic removal through the nasal cavity is the first‑line treatment for most microadenomas. Success rates (normalization of cortisol) range from 70–90 % for microadenomas and 40–60 % for macroadenomas.<sup>[4]</sup>
• Risks: CSF leak, hypopituitarism, diabetes insipidus, nasal complications.

Radiation therapy

• Fractionated stereotactic radiotherapy or Gamma Knife: Used when surgery is incomplete or not feasible. Hormonal remission may take 1–5 years; up to 50 % achieve remission.
• Potential late effects: pituitary hormone deficiencies, optic nerve injury.

Medical therapy (for persistent or recurrent disease)

• Adrenolytic agents:
  • Ketoconazole – blocks cortisol synthesis; monitor liver function.
  • Metyrapone – inhibits 11β‑hydroxylase; useful for rapid control.
  • Etomidate – IV infusion for severe, acute hypercortisolism.
• Pituitary‑directed drugs:
  • Pasireotide – somatostatin analog that suppresses ACTH; can cause hyperglycemia.
  • Mifepristone – glucocorticoid receptor antagonist; improves glucose control but does not lower cortisol levels.
• Medications are often used as bridge therapy while awaiting surgical/radiation results or when surgery fails.

Lifestyle & supportive care

• Low‑sodium diet and regular aerobic exercise to control blood pressure and weight.
• Calcium (1,200 mg) and vitamin D (800–1,000 IU) supplementation to protect bone health.
• Psychological counseling or support groups for mood disorders.
• Regular monitoring of glucose, blood pressure, and bone density.

Living with Cushing's Disease

Even after successful treatment, many patients experience lingering effects and require ongoing care.

Monitoring schedule

• First 12 months post‑treatment: cortisol (UFC), ACTH, and clinical assessment every 3 months.
• After remission is stable: semi‑annual checks for 2–3 years, then annual lifelong surveillance.

Daily management tips

• Nutrition: Emphasize whole grains, lean protein, plenty of vegetables, and limit processed foods and added sugars.
• Physical activity: Aim for 150 minutes of moderate‑intensity aerobic exercise weekly plus resistance training twice a week.
• Sleep hygiene: Keep a consistent bedtime routine; limit caffeine after noon.
• Stress reduction: Mindfulness, yoga, or gentle tai chi can help mitigate cortisol‑related mood swings.
• Medication adherence: Keep a pill organizer; set reminders for any ongoing hormone replacement (e.g., thyroxine, hydrocortisone).
• Vaccinations: Annual influenza vaccine and up‑to‑date pneumococcal vaccination due to prior immunosuppression.

Psychosocial support

Feelings of embarrassment about body changes are common. Joining a Cushing’s support network (e.g., Cushing’s Support Community) can provide emotional relief and practical advice on clothing, makeup, or coping strategies.

Prevention

Because Cushing’s disease results from a spontaneous pituitary tumor, primary prevention is limited. However, risk reduction strategies focus on minimizing factors that could precipitate pituitary hyperplasia or exacerbate cortisol excess.

• Avoid long‑term high‑dose glucocorticoid therapy unless medically necessary; discuss taper plans with your doctor.
• Maintain a healthy weight and blood pressure to lessen the impact of any future cortisol elevation.
• Promptly evaluate persistent “cushingoid” symptoms (e.g., rapid weight gain, bruising) rather than attributing them solely to lifestyle.

Complications

If cortisol excess remains uncontrolled, multiple organ systems can be permanently damaged.

• Cardiovascular disease: Accelerated atherosclerosis leading to heart attacks or strokes.
• Diabetes mellitus: Persistent hyperglycemia may become insulin‑dependent.
• Severe osteoporosis: Height loss, vertebral compression fractures, and reduced quality of life.
• Infections: Opportunistic bacterial, fungal, or viral infections due to immune suppression.
• Psychiatric sequelae: Chronic depression, anxiety, or cognitive deficits that may not fully resolve.
• Reproductive issues: Infertility, erectile dysfunction, or persistent menstrual disturbances.
• Mortality: Untreated Cushing’s disease carries a 5‑year mortality rate of up to 50 %; early diagnosis and treatment dramatically improve survival.<sup>[5]</sup>

When to Seek Emergency Care

References

1. NIH National Institute of Diabetes and Digestive and Kidney Diseases. “Cushing’s Syndrome.” 2023.
2. Mayo Clinic. “Cushing’s disease.” Updated 2024.
3. World Health Organization. “Rare diseases: an overview.” 2022.
4. Cleveland Clinic. “Transsphenoidal Surgery for Cushing’s Disease.” 2023.
5. European Journal of Endocrinology. “Long‑term outcomes of Cushing’s disease: a systematic review.” 2021;184(5):483‑495.

```